Physician profile
Raymond A Kahn
NPI 1346243581
$4,685.41
in general payments reported to CMS, 2019-2025
29 companies · $857 in 2025
The $857 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $496 · 2021: $604 · 2022: $744 · 2023: $601 · 2024: $570 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $646.34 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $482.81 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $356.69 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Glaxosmithkline, LLC. | $354.47 | 2019-2025 | Bexsero, Penmenvy |
| Supernus Pharmaceuticals, INC. | $343.40 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $310.90 | 2019-2023 | Dyanavel Xr |
| Neos Therapeutics, LP | $283.33 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $282.27 | 2020-2022 | |
| Sanofi Pasteur INC. | $206.31 | 2021-2025 | |
| Noven Therapeutics, LLC | $186.83 | 2024-2025 | Xelstrym |
| Pfizer INC. | $176.64 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $148.65 | 2019-2024 | Flumist Quadrivalent |
| Ultragenyx Pharmaceutical INC. | $123.59 | 2019 | |
| Noven Pharmaceuticals, INC. | $121.86 | 2024 | Xelstrym |
| Cranial Technologies, INC | $117.35 | 2020-2025 | Doc Band |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $84.44 | 2025 | |
| Adlon Therapeutics L.P. | $76.43 | 2019-2020 | |
| Genentech USA, INC. | $61.58 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $60.03 | 2019-2025 | Relexxii |
| Seqirus USA INC | $44.20 | 2022-2024 | Flucelvax |
| Collegium Pharmaceutical, INC. | $39.88 | 2025 | Jornay Pm |
| Aytu Biopharma, INC. | $29.87 | 2024 | Karbinal |
| Cumberland Pharmaceuticals, INC. | $28.68 | 2023-2024 | Kristalose |
| Abbvie INC. | $27.19 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.47 | 2025 | |
| Shire North American Group INC | $20.84 | 2019 | |
| Pharming Healthcare, INC. | $19.27 | 2023 | Ruconest |
| Sobi, INC | $18.39 | 2022 | |
| Dermira, INC. | $11.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.